HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aveeno’s Premier Hair-Care Range Builds Upon Skin-Care Equity

This article was originally published in The Rose Sheet

Executive Summary

Aveeno is looking to capitalize on its reputation for natural-based skin care products with the launch of Aveeno Nourish+, its first hair-care line, which contains a wheat protein to revive damaged hair

You may also be interested in...



J&J reports Q2

Skin care continues to drive performance of firm's consumer business, booking operational growth of 5.9% for fiscal 2009 second quarter. Neutrogena and Aveeno again are standout brands, the latter having launched Nourish+ hair care -- formulated with a wheat protein complex to revitalize damaged hair -- during the quarter (1"The Rose Sheet" March 2, 2009). Firm's U.S. skin-care sales advanced 8.4% operationally, while international sales were up 3.8% partly on strength of products acquired last year from Chinese brand Dabao (2"The Rose Sheet" Aug. 4, 2008, In Brief). Oral-care revenue was down 5.9% in the U.S. due to "softness in the category," but increased 9.5% abroad on an operational basis, with Listerine leading the charge. Overall consumer sales declined 4.5% to $3.9 bil. in what CFO Dominic Caruso calls "one of the most challenging quarters for year-over-year comparisons in [firm's] history" owing to tighter consumer spending, stiffer private-label competition and the loss of market exclusivity as patents expired for J&J drugs including Risperdal and Topomax. However, based on recent launches, approvals and filings with FDA, firm says it has "one of the most robust pharmaceutical pipelines in [its] history." Total company sales in Q2 were $15.2 bil. worldwide, down 7.4%, on a reported basis

P&G Restores Volume Growth In Beauty, Grooming After Pricing Run

Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS015987

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel